Abstract Shortly after the discovery of human herpesvirus 6 (HHV-6), two distinct variants, HHV-6A and HHV-6B, were identified. In 2012, the International Committee on Taxonomy of Viruses (ICTV) classified HHV-6A and HHV-6B as separate viruses. This review outlines several of the documented epidemiological, biological, and immunological distinctions between HHV-6A and HHV-6B, which support the ICTV classification. The utilization of virus-specific clinical and laboratory assays for distinguishing HHV-6A and HHV-6B is now required for further classification. For clarity in biological and clinical distinctions between HHV-6A and HHV-6B, scientists and physicians are herein urged, where possible, to differentiate carefully between HHV-6A and HHV-6B in all future publications.
Introduction and classification history
In 1986, a new virus was isolated in the USA from patients with AIDS as well as lymphoproliferative disorders [111] . Initially designated ''human B-lymphotropic virus (HBLV)'', the virus was renamed human herpesvirus 6 (HHV-6) (GS strain), following herpesvirus nomenclature guidelines, soon thereafter [2] . In 1987 and 1988, independent isolates were obtained from AIDS patients in Africa, designated U1102 (from Uganda) [50] and Z29 (from Zaire) [80, 124] . As other strains were isolated from various geographic regions and clinical settings, it became gradually apparent that all HHV-6 isolates could be included in one of two well-defined groups, differing in their molecular, epidemiological and biological properties [4, 16, 71, 113, 129] . The two groups showed different in vitro tropism for selected T cell lines, specific immunological reactivity with monoclonal antibodies, distinct patterns of restriction endonuclease sites, and specific and conserved interstrain variations in their DNA sequences [68, 69, 71] .
In the early 1990s, the scientific community debated whether the two groups simply reflected a normal population heterogeneity within a single virus species [113] , and in 1992 a first consensus was reached to designate such groups as two variants of the same species: HHV-6A and HHV-6B [1] . This decision was based on two main factors: (i) the interspecies divergence of nucleic acids was remarkably low and (ii) there was limited knowledge of differential epidemiology and pathogenic potential [1] . However, as new evidence continued to accrue, several authors began to suggest that the two variants be recognized as distinct viruses [22, 24, 32, 45] .
Genomic sequencing has now confirmed distinctions between HHV-6A and HHV-6B and relationships to the herpesvirus family overall. The genomes of the these two viruses are co-linear and share an overall identity of 90 %, but divergence of specific sequences [e.g., the immediateearly (IE) region] is higher than 30 %, some from splicing differences [47, 58, 67] , and there are clear functional differences in the IE1 gene of HHV-6A and HHV-6B [59, 70] . Remarkably, even though the IE1 gene differs substantially between HHV-6A and HHV-6B, this region is highly conserved ([95 %) within clinical and laboratory isolates of each virus [116] . Analysis of different viral strains shows that even highly conserved sequences with homology higher than 95 %, such as gH, gB and U94, as well as divergent genes such as gN, gO, and U83 chemokine, are characterized by specific amino acid signatures, which permit distinctions between the two viruses [5, 56, 107] . Furthermore, several reports have shown that the splicing pattern and temporal regulation of transcription of selected genes are different [47, 67, 92, 102, 103] . So far, these distinctions and the absence of evidence of intervariant recombination in common circulating viruses suggest that the two groups do occupy different ecological niches in vivo [24] .
An Ad Hoc Committee on HHV-6A & HHV-6B Genomic Divergence was formed in 2009 to generate an official proposal to recognize HHV-6A and HHV-6B as distinct viruses, which was submitted to the ICTV in 2010. In 2012, the ICTV officially ratified the classification of HHV-6A and HHV-6B as distinct viruses, replacing species Human herpesvirus 6 with Human herpesvirus 6A and Human herpesvirus 6B in the genus Roseolovirus, subfamily Betaherpesvirinae, family Herpesviridae, order Herpesvirales. Human herpesvirus 6A has been designated as the type species in this genus [6] .
The following is a detailed summary of several known distinctions between HHV-6A and HHV-6B, which ultimately led or added support to the classification of these agents as separate and distinct viruses.
Distinct epidemiology and disease associations . HHV-6A has been found predominantly in the CNS of a subset of patients with MS, and active HHV-6A infection has been detected in blood [8, 9, 11] and in CSF [110] of patients with relapsing/remitting MS [8-10, 14, 20, 110, 115, 131] . Marmosets inoculated with HHV-6A intravenously exhibited neurological symptoms, whereas those inoculated with HHV-6B were asymptomatic [75] . A strain of HHV-6A has also recently been isolated from the fluid specimens from a glioma cyst [112, 121] , the modality and/or affinity of receptor interaction seem to differ between the two viruses. It has been suggested that HHV-6A (U1102 or GS), but not HHV-6B, can induce CD46-mediated cellcell fusion without viral replication [93] through a tetrameric complex composed of glycoproteins gH, gL, and gQ1, and gQ2 [94, 122] . However, some groups have reported that HHV-6B is also able to induce cell-cell fusion without viral replication [99] . 4. CD134, a member of the TNF receptor superfamily present on activated T lymphocytes, has recently been identified as a receptor molecule for HHV-6B, selectively interacting with the gH/gL/gQ1/gQ2 complex of HHV-6B [123] . 5. The HHV-6A and HHV-6B gO gene products have 76.8% amino acid sequence identity, which is much lower than the identity between other glycoproteins. 
Distinction of HHV-6A vs. HHV-6B in publications
The lack of clear distinction between HHV-6A and HHV-6B in the literature makes it difficult to properly assess epidemiological differences and etiologic associations. In light of the ICTV's official reclassification, the utilization of virus-specific clinical and laboratory assays for HHV-6A
and HHV-6B is especially crucial [23, 26, 64, 66] . However, because HHV-6A can be present at lower copy numbers than HHV-6B, assays that rely strictly on melting point analysis for differentiation may be biased toward the detection of HHV-6B, resulting in further confusion [81] . Moreover, reliance on single SNPs, for example in restriction enzyme assays or using 'specific' primers or probes in real-time PCR assays, can be misinterpreted due to strain variation unless an extensive characterization of laboratory-adapted and clinical strains has been performed [26] . Furthermore, serology currently cannot differentiate between HHV-6A and HHV-6B. To avoid this complication, the use of comprehensive virus-specific assays is preferred, combined with confirmation using nucleotide sequencing [18, 26, 42, 55, 57] . In an effort to bring additional clarity to the important biological and clinical distinctions between HHV-6A and HHV-6B, we herein urge scientists and physicians to carefully differentiate, whenever possible, between HHV-6A and HHV-6B in all future publications. 
